Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canakinumab for the treatment of TNF-receptor associated periodic syndrome.

Expert review of clinical immunology - 1 Jun 2017

La Torre F, Caparello M C, Cimaz R

Abstract excerpt

INTRODUCTION: TNF-receptor-associated periodic syndrome is an autoinflammatory disorder caused by mutations in TNF receptor superfamily 1A gene. The molecular pathogenesis of TRAPS remains unclear; it is known that a key role is played by mutations in TNFRSF1A that induce the hypersecretion of pro-inflammatory cytokines as well as IL-1β, resulting in uncontrolled inflammatory reactions. Furthermore, TNFRSF1A gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Antibodies, Monoclonal, Humanized
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Approval

Share to Hereditary Autoinflammatory Diseases

Share to Interleukin-1beta

Share to Receptors, Tumor Necrosis Factor, Type I

Source

Identifiers

PMID: 28454496
DOI: 10.1080/1744666X.2017.1324783

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canakinumab for the treatment of TNF-receptor associated periodic syndrome.PMID 28454496Read ↗

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.Semantic proximity Read ↗

Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.Semantic proximity Read ↗

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).Semantic proximity Read ↗

[TNF receptor-associated periodic syndrome (TRAPS) in Japan: clinical characterization, pathogenesis, diagnostic criteria, and treatment].Semantic proximity Read ↗

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.Semantic proximity Read ↗

Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.Semantic proximity Read ↗

Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives.Semantic proximity Read ↗

[Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art].Semantic proximity Read ↗

Setting up TRAPS.Semantic proximity Read ↗

TNF receptor-associated periodic syndrome (TRAPS): Description of a novel TNFRSF1A mutation and response to etanerceptSemantic proximity Read ↗

TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder.Semantic proximity Read ↗

The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.